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Abstract As previously shown for [3H-galactosyl]ceramide, the
breakdown of [3H-galactosyl]sphingosine was reduced in prosa-
posin-deficient skin fibroblast homogenates. Galactosylsphingo-
sine hydrolysis was also deficient in cell homogenates from
Krabbe’s disease (L-galactocerebrosidase-deficient) patients, but
not acid L-galactosidase-deficient patients. Moreover, hydrolysis
of galactosylsphingosine in the prosaposin-deficient cell ho-
mogenates could be partially restored by adding pure saposin A
or C, thereby identifying these saposins as essential facilitators of
galactosylsphingosine hydrolysis. By contrast, saposins B and D
had little effect on galactosylsphingosine hydrolysis in the
prosaposin-deficient cells. The reduced galactosylsphingosine
turnover in prosaposin-deficiency suggests that there could be a
pathogenetic cerebral accumulation of galactosylsphingosine in
this disorder. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
The degradation of sphingolipids by lysosomal lipid hydro-
lases is facilitated by sphingolipid activator proteins, with the
enzymatic deglycosylation of monohexosyl and small oligo-
saccharyl ceramides and the desulfation of sulfogalactosyl cer-
amide being dependent on activator proteins (for review, see
[1]). In addition, the enzymatic hydrolysis of ceramide to
sphingosine and fatty acid is also mediated by an activator
protein [2,3].
Prosaposin is a precursor protein giving rise to four saposin
(sap) activators, sap A, B, C and D, through proteolytic cleav-
age [4]. Two mechanisms of action appear to be involved in
sphingolipid activator function. Some activators (e.g. sap B)
mobilise glycosphingolipids by loosening the sphingolipid’s
ceramide moiety within the membrane, thereby making the
sphingolipid’s glycosyl groups more accessible to sphingolipid
hydrolases [1]. Other activators (e.g. sap C) bind to a given
lipid hydrolase (e.g. glucosylceramide-L-glucosidase = L-gluco-
cerebrosidase), rather than the sphingolipid, and the ensuing
activator/enzyme complex is more e¡ective at hydrolysing the
sphingolipid substrate [1,5].
The investigation of activator-de¢cient sphingolipidoses (for
review, see [1]) has helped to elucidate the metabolic role of
sphingolipid activator proteins. For example, the crucial role
for sap B in the solubilisation of some sphingolipid substrates
(e.g. sulfatide and globotriaosylceramide) has been clearly es-
tablished (for review, see [1]). Studies on sap B- and sap C-
de¢cient cases, as well as the prosaposin-de¢cient (Prosap-d)
patients [3,6^9], where all four saposins are absent, have high-
lighted the dependence of hydrolytic degradation of a number
of sphingolipids on one or more saposins (for reviews, see
[1,4]). In particular, analysis of the Prosap-d cells provided
evidence for the crucial role of saposins in the degalactosyla-
tion of lactosylceramide [6] and galactosylceramide (GC) [9],
thereby supporting the hypothesis that sap A and/or sap C are
especially required for the hydrolysis of the monohexoside GC
[10].
In Krabbe’s disease, where the activity of L-galactocerebro-
sidase (GALC) is de¢cient, the degradation of both GC and
lyso-GC (galactosylsphingosine = psychosine; PS), which lacks
GC’s fatty acid moiety, is defective [11,12]. Given that sap A
and/or sap C activate the degalactosylation of GC by GALC
[9], we wondered whether these saposins might also assist
degalactosylation of PS by this enzyme. We have utilised Pro-
sap-d cells to investigate this possibility.
2. Materials and methods
2.1. Cell strains
Control, Prosap-d [6^9,13,14], GALC-de¢cient (early infantile and
late onset [15] Krabbe’s disease) and acid L-galactosidase (ABG)-de-
¢cient (early infantile GM1-gangliosidosis and juvenile Morquio-IVB
syndrome [16]) cells were grown from stocks of frozen skin ¢broblasts
in our diagnostic laboratory in Tu«bingen, Germany. Clinical informa-
tion for the relevant patients is provided in Table 1.
2.2. Cell culture and preparation of cell homogenates
Before use, the ¢broblasts were maintained for 1 week in standard
medium 199 (C.C. Pro GmbH, D-67433 Neustadt/Germany) with
glutamine and 10% (v/v) foetal calf serum under an atmosphere of
5% CO2. Prior to performing the enzyme assays, the cell monolayers
were washed twice with 0.9% (w/v) NaCl, and then 500 Wl H2O was
added to each 25 cm2 £ask. After freeze^thawing twice, the cellular
material was collected by scraping and the suspension was stirred for
2 min to give a homogeneous suspension.
2.3. Activator proteins
The preparation of crude sap C used in these studies was a post-
DE52 column, Con A-binding fraction [17] containing sap C and
minor components of sap A, B and D. Pure saposins, sap A, B, C
and D, were prepared from Gaucher’s disease spleen as described
[10,18] and their purity checked by SDS^PAGE and reverse phase
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high performance liquid chromatography (C4 column). Immunoblot-
ting using monospeci¢c antibodies (rabbit polyclonal anti-sap A [10],
anti-sap B [19] and anti-sap D [19] and mouse monoclonal anti-sap C
[20]) indicated that the speci¢c preparations were not contaminated
with other saposins, and this was con¢rmed by N-terminal sequence
analysis. Saposins were either added directly to the enzyme assays or,
alternatively, the saposin was added to the cell culture medium at the
indicated concentration 4 days prior to harvesting the cells.
2.4. Assay of psychosine-L-galactosidase (GALC-PS) activity
Radioactive PS was prepared from [3H]GC [21] by alkaline hydro-
lysis [22]; the GC having been labelled with tritium in the galactose
moiety using the tritium^borohydride procedure [23]. The [3H]PS,
which had a speci¢c radioactivity of 104 dps/nmol, was puri¢ed
from the deacylated preparation by preparative thin layer chromatog-
raphy (TLC). For each reaction, 33 pmol of the stock PS solution was
dried in a vial and then dissolved in 50 Wl bu¡er solution containing
0.3 M acetate, 0.016 M phosphate and 0.012 M citrate (sodium salts)
adjusted to pH 4.5. From 20 to 70 Wg protein of ¢broblast homoge-
nate in 100 Wl water was carefully admixed and the assay incubated
for 4 h at 37‡C. The reaction was stopped by adding 150 Wg unla-
belled galactose in 75 Wl water. The assay volume was reduced to 40
Wl, 80 Wl methanol was added and the mixture completely applied to a
silica-gel TLC plastic sheet (Macherey and Nagel, Du«ren, Germany,
number 805013). The sheet was chromatographed (16 cm) using
chloroform/methanol/water (14/6/1 by volume). The dried sheet was
then deactivated in a refrigerator at 6‡C for 20 min, and the cold sheet
was chromatographed a second time with the same solvent mixture.
The dried sheet was analysed with a linear radioscanner for radio-
activity, and the peaks corresponding to the enzymatically released
galactose and undegraded PS substrate were identi¢ed. Iodine vapours
were additionally helpful in localising the radioactive galactose, as
there was su⁄cient unlabelled galactose present to give an iodine-
positive spot. The galactose and PS spots were cut out, along with
the plastic backing sheet, and the radioactivity determined by liquid
scintillation counting. In control cell assays, about 15% of the radio-
activity from the added PS substrate was found in the galactose frac-
tion.
2.5. Assay of galactosylceramide-L-galactosidase (GALC-GC) activity
GALC activity was determined using [3H]GC as described [24].
3. Results
When compared to control cells, the GALC-PS activity was
almost completely de¢cient in cell lysates derived from infan-
tile Krabbe’s patients, and it was also profoundly de¢cient in
cells from two late onset Krabbe’s patients (numbers 1 and 2),
with cells from the third late onset patient (No. 3) having a
somewhat higher residual activity (Table 2). By contrast, in
ABG-de¢cient cells the GALC-PS activity was within the nor-
mal range (GM1-gangliosidosis patient) or relatively high (pa-
tient with Morquio IVB syndrome).
The activity of GALC-PS was also profoundly de¢cient in
cells from the Prosap-d patient [7,13] and foetus [8] (Table 2).
Cell preparations from the foetus (patient cells could not be
studied) showed a dramatic, approximately six fold, increase
in GALC-PS activity on addition of sap A or C to the assay
(for details, see Table 2), whereas in normal cell preparations,
the GALC-PS activity was increased by a factor of only 1.3
on the addition of 5 Wg sap C (Table 2).
The GALC-GC activity was characteristically de¢cient in
all Krabbe’s disease cell strains, with cells from the late onset
patients showing generally higher residual activities than those
from infantile patients (Table 2). A reduced GALC-GC activ-
ity was also con¢rmed for Prosap-d cell lysates (Table 2).
Whereas addition of sap C to the GALC-GC assay had min-
imal impact on substrate turnover (see also Section 4), prior
addition of sap C to the cell culture medium (30 Wg crude sap
C/ml) slightly increased (2.6 fold) the GALC-GC activity in
the cell lysates (Table 2). Unfortunately, we were unable to do
comparable experiments to assess the impact of pre-culturing
the Prosap-d cells with sap C-supplemented media on the
enzyme’s GALC-PS activity, due to insu⁄cient stocks of the
saposin.
Table 1
Clinical ¢ndings for the patients
Age in years at
diagnosis (last
report)
Clinical symptoms
Infantile Krabbe’s disease
No. 1 0.5 Severe leukodystrophic signs with spasticity, increased cerebrospinal £uid protein, reduced nerve
conduction velocities (similar to descriptions in [24])
No. 2 0.9 As in No. 1
No. 3 1.1 As in No. 1
No. 4 1.1 As in No. 1
Late onset Krabbe’s disease
No. 1 10 (12) Severe visual impairment, slightly ataxic movements, reduced nerve conduction velocities, neuro-imaged
demyelinating foci
No. 2 4 (17) Wheelchair-bound patient with contracted joints, atrophic muscles, severe scoliosis, visual impairment,
inability to speak but only slightly impaired intellect, neuro-imaged demyelinating foci
No. 3 6 (22) As in No. 2, but without scoliosis, and with additional symptoms including epileptic seizures, distinct
signs of dementia, and swallowing di⁄culties necessitating tube feeding (see also an earlier report [15])
ABG de¢ciency
GM1-gangliosidosis 2 Psychomotor retardation, muscle weakness, hepatosplenomegaly
Morquio IVB
syndrome
6 Corneal opacities, dysostosis multiplex, kyphoscoliosis, body length below the 3rd percentile [16]
Prosap-d
Patient 0.3 Directly after birth there were hyperkinetic motor abnormalities, fasciculation of tongue and face
muscles, spontaneous Babinski sign, generalised clonic seizures, hepatosplenomegaly, bone marrow
storage cells; child died at 16 weeks [7,8]
Foetus Pathology of generalised lipid storage [7,8,14]; pregnancy terminated at 20 weeks gestation
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4. Discussion
In previous in vivo studies, we found that the defective
turnover of GC in Prosap-d cells could be partially corrected
by the addition of sap A and/or sap C to the culture medium
[9]. The present in vitro investigations have clearly established
that GALC-PS activity is also de¢cient in Prosap-d cells. In
addition, the hydrolysis of PS could also be increased by
supplementation with sap A or sap C, indicating that the
GALC-PS defect in Prosap-d cells largely re£ected an absence
of saposins rather than a lack of functional GALC enzyme.
By contrast, there was only a slight saposin-mediated increase
in GALC-PS activity in normal cells.
In the Prosap-d cell lysates, the relative de¢ciency of
GALC-PS activity was similar to that for GALC-GC. In
this respect, the defect in GALC activity, as measured in
various in vitro assays ([7,8] and present manuscript), was
more marked in the Prosap-d lysates than the defect in L-
glucocerebrosidase activity [7,8]. This raised the possibility
that, in addition to the direct impact of the loss of saposin
activation, there may be a secondary impact on the amount of
GALC protein (discussed in [8,9]). In the present GALC-PS
assays, addition of sap A or C led to a large increase in
GALC-PS activity, up to values approaching those found
for some normal cell lysates, thereby indicating that there
was not a major loss of the GALC enzyme. However, due
to the wide normal control range for GALC-PS activity, it is
unclear whether this represents full recovery of GALC activ-
ity, so the possibility that there has been some impact on the
amount of GALC protein cannot be completely discounted at
this time. Indeed, the increased GALC-GC activity observed
after incubating the Prosap-d cells with sap C may re£ect an
impact on the level of GALC protein. A failure to totally
restore GALC activity on addition of sap A or C could also
re£ect some other de¢ciency, such as in the lipid microenvi-
ronment, of the in vitro assay system. Earlier studies have
indicated that activation of the enzyme requires an acidic
(phospho)lipid [25], and the large sphingolipid elevations in
the Prosap-d ¢broblasts [8] may also impact on the enzyme’s
activity. In addition, studies on the action of these two sap-
osins indicate that, at least as far as L-glucocerebrosidase
activity is concerned, they act synergistically [5,26]. Thus,
the absence of the alternative GALC saposin activator (A
or C), or indeed saps B and D, or perhaps prosaposin itself,
may have an additional detrimental e¡ect on GALC function.
However, in previous studies we found no further stimulation
of GC turnover when sap A- or C- treated Prosap-d cells were
supplemented with sap B or D [9]. It is also possible that the
absence of the prosaposin/saposin system suppressed the ac-
tivity of other potential PS-degrading enzymes, such as ABG,
which is known to degrade GC [27^29]. However, the present
GALC-PS results with ABG-de¢cient cells, as well as in vitro
studies demonstrating ABG’s relative inability to degrade PS
[12,27] compared to its appreciable GC-degrading activity
[27], do not support the view that PS is hydrolysed by
ABG. Compared to the GALC-PS activity, addition of sap
Table 2
Activity of speci¢c L-galactosidases in cultured ¢broblasts
Added saposin GALC-PS pmol/h/mg protein GALC-GC nmol/h/mg protein
Normal controls
Mean þ S.D. (n = 10) n.s.a.b 20.3 þ 7.9 0.895 þ 0.33
No. 11 n.s.a.b 26.9e
No. 11 5 Wg pure sap Cc 34.0e
Infantile Krabbe’s disease
No. 1 n.s.a.b 0.15 0.033
No. 2 n.s.a.b 0.16 0.040
No. 3 n.s.a.b 0.50 0.075
No. 4 n.s.a.b 0.66 0.027
Late onset Krabbe’s disease
No. 1 n.s.a.b 0.99 0.081
No. 2 n.s.a.b 1.06 0.101
No. 3 n.s.a.b 3.70 0.083
ABG de¢ciency
GM1-gangliosidosis n.s.a.b 15.0 0.85
Morquio IVB syndrome n.s.a.b 43.8 0.90
Prosap-d
Patienta n.s.a.b 1.70 0.069
Foetus n.s.a.b 1.57 0.125
Foetus 20 Wg crude sap Cc 9.23
Foetus 5 Wg pure sap Ac 9.88
Foetus 5 Wg pure sap Cc 10.2
Foetus 10 Wg pure sap Cc 0.167
Foetus 30 Wg/ml crude sap Cd 0.331
Except where otherwise indicated (see below), the results are the mean of triplicate assays. Clinical information for the patients is provided in
Table 1.
aSV40-transformed cells [13].
bn.s.a. indicates no saposin added.
cSaposin added to the enzyme assay.
dSaposin added to the cell culture medium.
eMean of duplicate assays.
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C to the in vitro GALC-GC assay reported here had minimal
impact on the enzyme’s activity. However, this probably re-
£ects the presence of taurocholate in the assay [25]. In earlier
studies using a liposomal assay system [8], addition of crude
sap C clearly stimulated GALC-GC activity approximately
three to ¢ve fold in both Prosap-d and normal cell lysates
(Paton, unpublished); the fold activation being similar to
that reported here for the GALC-PS activity in Prosap-d
cell lysates.
It has been postulated that PS has a pathophysiological role
in the neurodegeneration observed in Krabbe’s disease
[11,21,30], with the severe demyelination being attributed to
cerebral accumulation of the cytotoxic PS [30,31]. Our results
indicate that an accumulation of PS could result not only
from a de¢ciency of the GALC enzyme, but also from a
de¢ciency of sap A and/or C; both the enzyme and saposins
being essential for its degradation. This view is supported by
the recent observation that PS is elevated in a sap A-de¢cient
mouse model [32]. Moreover, since the hydrolysis of glucosyl-
ceramide by L-glucocerebrosidase is also dependent on sap A
and/or C [1,4,5,10], we predict that degradation of lyso-gluco-
sylceramide (glucosylsphingosine) would also be impaired
when these saposins are de¢cient. Just as PS has been linked
to pathogenesis in Krabbe’s disease, glucosylsphingosine cy-
totoxicity is thought to promote the neurodegeneration seen
in Gaucher’s disease types 2 and 3 [33].
Measuring the activity of GALC-PS in the absence and
presence of added sap A and/or C should also facilitate the
di⁄cult diagnosis of Prosap-d. A de¢cient GALC-PS activity,
which is responsive to added sap A/C, should be a character-
istic ¢nding in this disease, which has been rarely, and possi-
bly under-, diagnosed in humans. Indeed, human Prosap-d
has only recently been described for the second time [34] ;
the ¢ndings essentially con¢rming those from the original pa-
tient and foetal sib [6^8], and also paralleling the analogous
¢ndings from a Prosap-d murine model [35].
Until now, the in vivo action of saposins was thought to be
directed towards the turnover of hydrophobic, ceramide-based
sphingolipids. This is the ¢rst report of saposin-mediated hy-
drolysis of a more polar, natural, ceramide-free lyso-sphingo-
lipid substrate, a ¢nding which is consistent with the hypoth-
esis that sap A and sap C interact with the substrate
hydrolysing enzyme [1,4,5].
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